1 in 8 adults in the US has taken Ozempic or another GLP-1 drug, KFF survey finds [CNN]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNN
them – about 6% of adults, or more than 15 million people – are currently using a prescription, according to new survey data from KFF. The US Food and Drug Administration has reported shortages of the GLP-1 medications Ozempic, Wegovy and Mounjaro at various dosages over the past year as drugmakers have raced to keep up with skyrocketing demand. Last week, Novo Nordisk said that at least 25,000 people in the US are starting its drug Wegovy each week – five times more than were able to start the medicine each week in December. According to the new survey, most adults who have used these drugs have done so to manage chronic conditions such as diabetes or heart disease. More than 40% of respondents who have diabetes and about a quarter of those who have heart disease said they have used GLP-1 drugs. But about 2 in 5 adults used GLP-1 drugs solely to lose weight, the KFF poll found. Neither Ozempic nor Mounjaro is approved for weight loss specifically; the FDA greenlit them to tre
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- ADOCIA Announces Appointment of Mathieu-William Gilbert as Chief Operating Officer [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk launches national Wegovy® campaign, Power of Wegovy® [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®PR Newswire
- Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate [Yahoo! Finance]Yahoo! Finance
- Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 6/3/24 - Form 6-K
- 5/28/24 - Form 6-K
- 5/17/24 - Form 6-K
- NVO's page on the SEC website